β-Glucuronidase triggers extracellular MMAE release from an integrin-targeted conjugate

Abstract

A non-internalizing α_vβ₃ integrin ligand was conjugated to the anticancer drug MMAE through a β-glucuronidase-responsive linker. In the presence of β-glucuronidase, only the conjugate bearing a PEG4 spacer inhibited the proliferation of integrin-expressing cancer cells at low nanomolar concentrations, indicating important structural requirements for the efficacy of these therapeutics.